Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant…
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the…
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)…
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to…
CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the…
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk…
Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance…
ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100…
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…